Chuanxiong Rhizoma extracts prevent cholestatic liver injury by targeting H3K9ac-mediated and cholangiocyte-derived secretory protein PAI-1 and FN.
10.1016/S1875-5364(23)60416-9
- Author:
Yajing LI
1
;
Zhi MA
1
;
Mingning DING
1
;
Kexin JIA
1
;
Bing XU
2
;
Fei ZHOU
1
;
Ranyi LUO
1
;
Xiaoyong XUE
1
;
Ruiyu WU
2
;
Feng GAO
2
;
Xiaojiaoyang LI
3
Author Information
1. School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
2. School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100029, China.
3. School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China. Electronic address: xiaojiaoyang.li@bucm.edu.cn.
- Publication Type:Journal Article
- Keywords:
Cholangiocytes;
Cholestatic liver injury;
Chuanxiong Rhizoma;
Ductular reaction;
Hepatic stellate cell
- From:
Chinese Journal of Natural Medicines (English Ed.)
2023;21(9):694-709
- CountryChina
- Language:English
-
Abstract:
Chuanxiong Rhizoma (CX, the dried rhizome of Ligusticum wallichii Franch.), a well-known traditional Chinese medicine, is clinically used for treating cardiovascular, cerebrovascular and hepatobiliary diseases. Cholestatic liver damage is one of the chronic liver diseases with limited effective therapeutic strategies. Currently, little is known about the mechanism links between CX-induced anti-cholestatic action and intercellular communication between cholangiocytes and hepatic stellate cells (HSCs). The study aimed to evaluate the hepatoprotective activity of different CX extracts including the aqueous, alkaloid, phenolic acid and phthalide extracts of CX (CXAE, CXAL, CXPA and CXPHL) and investigate the intercellular communication-related mechanisms by which the most effective extracts work on cholestatic liver injury. The active compounds of different CX extracts were identified by UPLC-MS/MS. A cholestatic liver injury mouse model induced by bile duct ligation (BDL), and transforming growth factor-β (TGF-β)-treated human intrahepatic biliary epithelial cholangiocytes (HIBECs) and HSC cell line (LX-2 cells) were used for in vivo and in vitro studies. Histological and other biological techniques were also applied. The results indicated that CXAE, CXAL and CXPHL significantly reduced ductular reaction (DR) and improved liver fibrosis in the BDL mice. Meanwhile, both CXAE and CXPHL suppressed DR in injured HIBECs and reduced collagen contraction force and the expression of fibrosis biomarkers in LX-2 cells treated with TGF-β. CXPHL suppressed the transcription and transfer of plasminogen activator inhibitor-1 (PAI-1) and fibronectin (FN) from the 'DR-like' cholangiocytes to activated HSCs. Mechanistically, the inhibition of PAI-1 and FN by CXPHL was attributed to the untight combination of the acetyltransferase KAT2A and SMAD3, followdd by the suppression of histone 3 lysine 9 acetylation (H3K9ac)-mediated transcription in cholangiocytes. In conclusion, CXPHL exerts stronger anti-cholestatic activity in vivo and in vitro than other CX extracts, and its protective effect on the intracellular communication between cholangiocytes and HSCs is achieved by reducing KAT2A/H3K9ac-mediated transcription and release of PAI-1 and FN.
